Skip to main content
Erschienen in: World Journal of Surgery 2/2020

11.10.2019 | Original Scientific Report

Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies

verfasst von: F. M. Watzka, F. Meyer, J. I. Staubitz, C. Fottner, A. Schad, H. Lang, T. J. Musholt

Erschienen in: World Journal of Surgery | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

In contrast to exocrine pancreatic carcinomas, prognosis and treatment of pancreatic neuroendocrine neoplasms (PNEN) are significantly different. The variable growth pattern and associated clinical situation of functioning and non-functioning PNEN demand an individualized surgical approach. However, due to the scarce evidence associated with the rare disease, guidelines lack detailed recommendations for indication and for the required extent of surgical resection.

Methods

In a retrospective single-center study from 1990 to 2018, 239 patients with PNEN were identified. Clinical data were collected in the MaDoc database of the University Medical Center Mainz. A total of 155 non-functional PNEN were selected for further analysis.

Results

According to the classification of NET by the WHO in 2017, 28.8% (n = 40) of the tumors were G1, 61.9% (n = 86) G2, and 9.4% (n = 13) G3. In 73 patients, hepatic metastases were present. Sixty patients had lymph node metastasis. An R0 resection was achieved in 98 cases, an R1 situation in 10 cases. Five times, a tumor debulking was carried out (R2) and 5 times the operation was aborted without any resection because of the advanced tumor stage. A relapse occurred in 29 patients. Different prognostic factors (grade, tumor size, age) were analyzed. Grade-dependent 10-year overall survival rates were 79.5% (grade 1) and 60.1% (grade 2), respectively. The survival rate of grade 3 patients was limited to 66.7% after 13 months.

Conclusion

In our study, patients with non-functioning PNEN had a longer overall survival after successful R0 resection. The risk analysis confirmed a Ki-67 cutoff value of 5%, which divided a high- and low-risk group. Patients with a PNEC G3 (Ki-67 index > 50%) had a very poor prognosis.
Literatur
1.
Zurück zum Zitat Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRef Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRef
2.
Zurück zum Zitat Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas. Anal Autops Cases Dig Dis Sci 36:933–942CrossRef Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas. Anal Autops Cases Dig Dis Sci 36:933–942CrossRef
3.
Zurück zum Zitat Ito T, Igarashi H, Nakamura K et al (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 50:58–64CrossRef Ito T, Igarashi H, Nakamura K et al (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 50:58–64CrossRef
4.
Zurück zum Zitat Hallet J, Law CH, Cukier M et al (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation and outcomes. Cancer 121:589–597CrossRef Hallet J, Law CH, Cukier M et al (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation and outcomes. Cancer 121:589–597CrossRef
5.
Zurück zum Zitat Frilling A, Modlin IM, Kidd M et al (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15:e8–21CrossRef Frilling A, Modlin IM, Kidd M et al (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15:e8–21CrossRef
6.
Zurück zum Zitat Fesinmeyer MD, Austin MA, Li CI et al (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev 14:1766–1773CrossRef Fesinmeyer MD, Austin MA, Li CI et al (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev 14:1766–1773CrossRef
7.
Zurück zum Zitat Gratian L, Pura J, Dinan M et al (2014) Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann Surg Oncol 21:3515–3521CrossRef Gratian L, Pura J, Dinan M et al (2014) Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann Surg Oncol 21:3515–3521CrossRef
8.
Zurück zum Zitat Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–171CrossRef Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–171CrossRef
9.
Zurück zum Zitat Rinke A, Wiedenmann B, Auernhammer C et al (2018) Practice guideline neuroendocrine tumors—AWMF-Reg. 021-27. Z Gastroenterol 56:583–681CrossRef Rinke A, Wiedenmann B, Auernhammer C et al (2018) Practice guideline neuroendocrine tumors—AWMF-Reg. 021-27. Z Gastroenterol 56:583–681CrossRef
10.
Zurück zum Zitat Kulke MH, Shah MH, Benson AB 3rd et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw JNCCN 13:78–108CrossRef Kulke MH, Shah MH, Benson AB 3rd et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw JNCCN 13:78–108CrossRef
11.
Zurück zum Zitat Ferrone CR, Tang LH, Tomlinson J et al (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25:5609–5615CrossRef Ferrone CR, Tang LH, Tomlinson J et al (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25:5609–5615CrossRef
12.
Zurück zum Zitat Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRef Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRef
13.
Zurück zum Zitat Liszka L (2016) Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas. Pol J Pathol 67:318–331CrossRef Liszka L (2016) Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas. Pol J Pathol 67:318–331CrossRef
14.
Zurück zum Zitat Hauck L, Bitzer M, Malek N et al (2016) Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors. Scand J Gastroenterol 51:55–59CrossRef Hauck L, Bitzer M, Malek N et al (2016) Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors. Scand J Gastroenterol 51:55–59CrossRef
15.
Zurück zum Zitat Genc CG, Jilesen AP, Partelli S et al (2018) A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg 267:1148–1154CrossRef Genc CG, Jilesen AP, Partelli S et al (2018) A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg 267:1148–1154CrossRef
16.
Zurück zum Zitat Panzuto F, Boninsegna L, Fazio N et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29:2372–2377CrossRef Panzuto F, Boninsegna L, Fazio N et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29:2372–2377CrossRef
17.
Zurück zum Zitat Partelli S, Maurizi A, Tamburrino D et al (2014) Surgical management of pancreatic neuroendocrine neoplasms. Ann Saudi Med 34:1–5CrossRef Partelli S, Maurizi A, Tamburrino D et al (2014) Surgical management of pancreatic neuroendocrine neoplasms. Ann Saudi Med 34:1–5CrossRef
18.
Zurück zum Zitat D’Haese JG, Tosolini C, Ceyhan GO et al (2014) Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol 20:13893–13898CrossRef D’Haese JG, Tosolini C, Ceyhan GO et al (2014) Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol 20:13893–13898CrossRef
19.
Zurück zum Zitat Radu EC, Saizu AI, Grigorescu RR et al (2018) Metastatic neuroendocrine pancreatic tumor—case report. J Med Life 11:57–61PubMedPubMedCentral Radu EC, Saizu AI, Grigorescu RR et al (2018) Metastatic neuroendocrine pancreatic tumor—case report. J Med Life 11:57–61PubMedPubMedCentral
20.
Zurück zum Zitat Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRef Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRef
21.
Zurück zum Zitat Watzka FM, Fottner C, Miederer M et al (2015) Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbecks Arch Surg 400:349–358CrossRef Watzka FM, Fottner C, Miederer M et al (2015) Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbecks Arch Surg 400:349–358CrossRef
23.
Zurück zum Zitat Ricci C, Casadei R, Taffurelli G et al (2016) Validation of the 2010 WHO classification and a new prognostic proposal: a single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. Pancreatology 16:403–410CrossRef Ricci C, Casadei R, Taffurelli G et al (2016) Validation of the 2010 WHO classification and a new prognostic proposal: a single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. Pancreatology 16:403–410CrossRef
24.
Zurück zum Zitat Scarpa A, Mantovani W, Capelli P et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23:824–833CrossRef Scarpa A, Mantovani W, Capelli P et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23:824–833CrossRef
Metadaten
Titel
Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies
verfasst von
F. M. Watzka
F. Meyer
J. I. Staubitz
C. Fottner
A. Schad
H. Lang
T. J. Musholt
Publikationsdatum
11.10.2019
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 2/2020
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-019-05220-7

Weitere Artikel der Ausgabe 2/2020

World Journal of Surgery 2/2020 Zur Ausgabe

Surgical Symposium Contribution

‘Old Fashioned’ Open Adrenalectomy

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.